PCM
STLN

Portolan Capital Management’s Starling Oncology STLN Stock Holding History

Portolan Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-221,512
Closed -$454K – 155
2025
Q2 		$454K Buy
+221,512
New +$554K 0.03% 116

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $413M AUM 109.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Portolan Capital Management's STLN Position: Q3 2025 in Review

Portolan Capital Management sold out of Starling Oncology (STLN) in Q3 2025, closing a stake of 221,512 shares — an estimated $454K sold.

Portolan Capital Management first reported a position in STLN in Q2 2025 and held it in 1 quarter. The position peaked at $454K in Q2 2025. 108 funds tracked by Wall St. Rank hold STLN as of Q3 2025.

  • Portolan Capital Management reported no remaining Starling Oncology position as of Q3 2025 after selling out during the quarter.
  • Portolan Capital Management sold 221,512 Starling Oncology shares in Q3 2025, an estimated $454K.
  • Portolan Capital Management first reported a position in Starling Oncology in Q2 2025 and held it in 1 quarter.
  • Portolan Capital Management's Starling Oncology position peaked at $454K in Q2 2025.
  • 108 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2025.

Based on Portolan Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.